Hyloris Pharmaceuticals SA

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January

European active pharmaceutical ingredients specialist EuroAPI says it has moved “into a new chapter” for the company after appointing David Seignolle as its new chief executive officer and Emmanuel Bl

Hyloris and Rosemont Pharmaceuticals have struck up a US partnership on Hyloris’ proprietary valacyclovir oral suspension product, which will see Rosemont commercialize the antiviral in the US. Under

Value-added medicines specialist Hyloris Pharmaceuticals SA has via its partner AFT Pharmaceuticals struck an exclusive licensing agreement in China for its Maxigesic IV (paracetamol/ibuprofen) solu